KAUST's Laboratory of Stem Cells and Diseases, led by Assistant Professor Antonio Adamo, uses induced pluripotent stem cells (iPSCs) to model diseases like diabetes. The lab employs a reprogramming technique to revert patient fibroblasts into iPSCs, enabling the study of disease progression in vitro. Adamo's research focuses on enzymes and disregulated transcriptional/epigenetic mechanisms to understand disease onset. Why it matters: This research contributes to regenerative medicine and offers insights into metabolic diseases relevant to the GCC region.
Researchers at KAUST and Peking University Third Hospital have created a novel blastoid model for studying early human development using extended pluripotent stem cells (EPSCs). The blastoid is a 3D cell model mimicking the blastocyst phase, avoiding ethical concerns associated with using human embryos. The team showed that blastoids can be cultured to mimic post-implantation development, offering insights into early cell lineages. Why it matters: This innovation provides a way to study human embryogenesis without the ethical constraints of using actual embryos, potentially advancing our understanding of miscarriage and birth defects.
MBZUAI's Professor Le Song is developing an AI-driven simulation to model the human body at societal, organ, tissue, cellular, and molecular levels. The goal is to reduce the time and cost associated with bringing new medicines to market by removing the need for wet lab biological research. Song aims to create a comprehensive model using machine learning. Why it matters: This research could revolutionize drug discovery in the region by accelerating the development process and reducing reliance on traditional research methods.
Shahar Harel, Head of AI at Quris, presented a BIO-AI approach to drug safety assessment using a 'patient-on-a-chip' platform. This platform simulates the human body and generates high-frequency microscopy and biochemical data on drug interactions, considering patient genomics and ethnicity. The data is used to train multimodal deep learning models to predict drug safety and provide patient-specific recommendations. Why it matters: This approach offers a potential alternative to animal models, promising faster and more personalized drug development while reducing safety concerns.
MBZUAI is developing AI-powered applications to help reduce malaria's impact in Indonesia, supported by Sheikh Mohamed bin Zayed Al Nahyan's Reaching the Last Mile initiative. The applications use sensory data fusion to create "digital twins" for precise weather forecasting and real-time environmental representation. AI and clustering analysis identify recurring features contributing to malaria outbreaks, enabling preventative measures and early treatment. Why it matters: This project demonstrates AI's potential in combating climate-sensitive diseases and improving public health in vulnerable regions.